The quest for an infectious agent that may account for cases of Hodgkin's disease (HD) especially in young adults has proven vain until lately. We have recently reported findings that suggested the presence of measles virus (MV) antigens and MV RNA in the tissues of patients with HD. Support for an association between MV and HD has been provided by recent epidemiological findings relating the occurrence of HD to exposure to measles in pregnancy and the perinatal period. We now present further evidence of this putative association based on immunohistochemical, reverse transcriptase -polymerase chain reaction (RT -PCR) and in situ hybridisation studies (ISH) on HD tissues. Biopsies from 82 (54.3%) of our cohort of 154 patients showed a positive immunostain with at least two of the anti-measles antibodies used. Latent membrane protein-1 immunostaining for Epstein -Barr virus was positive in 46 (31.1%) of the patients examined. Reverse transcriptase -PCR and ISH for measles RNA were positive in seven and 10 of 28 patients, respectively. Preliminary clinicopathological associations between MV and HD are noted in this study, but no causal relationship can be claimed at this stage.
We investigated the ability of FTIR-microscopy to define spectral changes between drug-sensitive and drug-resistant human melanoma cells. As a model system, a resistant melanoma cell line (GAC) was selected with cisplatin from parental (GA) cells. Using Fourier transform infrared spectroscopy (FTIR) we investigated the ability to differentiate between the resistant variant derived from the sensitive parental cell line, in the absence of cisplatin. We determined and validated spectral parameters (biomarkers) that differentiated between the two cell lines. By applying the principal component analysis (PCA) model, we reduced the original data size to six principal components. We detected a significant and consistent increase in the cell's DNA/RNA ratio as well as an increase in the lipid/protein ratio in the resistant cells. These results strongly support the potential of developing FTIR microspectroscopy as a simple, reagent-free method for the identification of drug-resistant cells. Rapid detection of tumors resistant to a particular drug, should contribute to the ability of the physician to choose an effective treatment protocol.
Ovarian cancer (OC) is the second most common type of gynecological malignancy; it has poor survival rates and is frequently (>75%) diagnosed at an advanced stage. Platinum-based chemotherapy, with, e.g., carboplatin, is the standard of care for OC, but toxicity and acquired resistance to therapy have proven challenging. Despite advances in OC diagnosis and treatment, approximately 85% of patients will experience relapse, mainly due to chemoresistance. The latter is attributed to alterations in the cancer cells and is also mediated by tumor microenvironment (TME). Recently, we reported the synthesis of a platinum (IV) prodrug that exhibits equal potency toward platinum-sensitive and resistant OC cell lines. Here, we investigated the effect of TME on platinum sensitivity. Co-culture of OC cells with murine or human mesenchymal stem cells (MS-5 and HS-5, respectively) rendered them resistant to chemotherapeutic agents, including platinum, paclitaxel and colchicine. Platinum resistance was also conferred by co-culture with differentiated murine adipocyte progenitor cells. Exposure of OC cells to chemotherapeutic agents resulted in activation of phospho-ERK1/2. Co-culture with MS-5, which conferred drug resistance, was accompanied by blockage of phospho-ERK1/2 activation. The flavonoids fisetin and quercetin were active in restoring ERK phosphorylation, as well as sensitivity to platinum compounds. Exposure of OC cells to cobimetinib—a MEK1 inhibitor that also inhibits extracellular signal-regulated kinase (ERK) phosphorylation—which resulted in reduced sensitivity to the platinum compound. This suggests that ERK activity is involved in mediating the function of flavonoids in restoring platinum sensitivity to OC co-cultured with cellular components of the TME. Our data show the potential of combining flavonoids with standard therapy to restore drug sensitivity to OC cells and overcome TME-mediated platinum drug resistance.
Several
naturally occurring dietary polyphenols with chemopreventive
or anticancer properties are topoisomerase II poisons. To identify
additional phytochemicals that enhance topoisomerase II-mediated DNA
cleavage, a library of 341 Mediterranean plant extracts was screened
for activity against human topoisomerase IIα. An extract from Phillyrea latifolia L., a member of the olive tree family,
displayed high activity against the human enzyme. On the basis of
previous metabolomics studies, we identified several polyphenols (hydroxytyrosol,
oleuropein, verbascoside, tyrosol, and caffeic acid) as potential
candidates for topoisomerase II poisons. Of these, hydroxytyrosol,
oleuropein, and verbascoside enhanced topoisomerase II-mediated DNA
cleavage. The potency of these olive metabolites increased 10–100-fold
in the presence of an oxidant. Hydroxytyrosol, oleuropein, and verbascoside
displayed hallmark characteristics of covalent topoisomerase II poisons.
(1) The activity of the metabolites was abrogated by a reducing agent.
(2) Compounds inhibited topoisomerase II activity when they were incubated
with the enzyme prior to the addition of DNA. (3) Compounds were unable
to poison a topoisomerase IIα construct that lacked the N-terminal
domain. Because hydroxytyrosol, oleuropein, and verbascoside are broadly
distributed across the olive family, extracts from the leaves, bark,
and fruit of 11 olive tree species were tested for activity against
human topoisomerase IIα. Several of the extracts enhanced enzyme-mediated
DNA cleavage. Finally, a commercial olive leaf supplement and extra
virgin olive oils pressed from a variety of Olea europea subspecies enhanced DNA cleavage mediated by topoisomerase IIα.
Thus, olive metabolites appear to act as topoisomerase II poisons
in complex formulations intended for human dietary consumption.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.